FDA clears Ozempic for cardiovascular risk reduction in adults with type 2 diabetes and heart disease
Federal regulators added a heart-protection indication to Ozempic for a defined group of diabetes patients, though the documents do not state how large the benefit was.
On January 16, 2020, the FDA cleared a new indication for Ozempic (semaglutide) injection: reducing the risk of major adverse cardiovascular events in adults who have type 2 diabetes and established cardiovascular disease [1].
The agency's letter spells out those events as cardiovascular death, non-fatal myocardial infarction or non-fatal stroke [1]. Novo Nordisk submitted the request as a prior-approval supplemental new drug application on March 20, 2019, and the approval took effect the day the letter was signed [1]. The same action revised the prescribing information to reflect trial results [1].
That trial was SUSTAIN 6, described in the letter as a long-term, randomized, double-blind, placebo-controlled, multinational, multi-center cardiovascular outcomes study of semaglutide in people with type 2 diabetes [1]. It is registered with the National Library of Medicine as NCT01720446 [2].
The size of the risk reduction seen in SUSTAIN 6 is not given in the approval letter, and the registry record for the trial does not include outcome numbers [1][2]. So the degree of benefit behind the new indication has not been described in these documents.
Two other details appear in the letter. The FDA waived the pediatric study requirement for the application, saying the necessary studies are "impossible or highly impracticable" [1]. The approval was signed by Lisa B. Yanoff, M.D., acting director of the Division of Metabolism and Endocrinology Products in the agency's drug evaluation office [1].
Ozempic's first approval came on December 5, 2017, for type 2 diabetes [3]. The label has widened several times since. A January 2025 action added reducing the risk of worsening kidney disease and cardiovascular death in adults with type 2 diabetes and chronic kidney disease [3]. In late January 2026, an oral semaglutide product previously sold as Rybelsus was rebranded as Ozempic tablets [3].
Why it matters for patients
The scope of the heart indication is limited. It applies to people with type 2 diabetes who also carry a diagnosis of established cardiovascular disease, which the letter treats as a qualifying condition rather than a list of specific events [1]. Which patients fit that description is a matter for their clinicians; the approval documents do not itemize the qualifying conditions or explain how benefit was measured person by person [1].
Semaglutide is sold under several brand names with different approved uses. Wegovy, approved June 4, 2021, is the same molecule but is marketed for weight reduction and for cardiovascular risk reduction in people with obesity or overweight [3]. The January 2020 decision described here applies to Ozempic, not to those other products [1][3].
Ozempic carries a boxed warning about thyroid C-cell tumors. Labeled warnings and precautions also cover acute pancreatitis, diabetic retinopathy complications, hypoglycemia, acute kidney injury from volume depletion, severe gastrointestinal reactions, serious hypersensitivity, acute gallbladder disease, and pulmonary aspiration during general anesthesia or deep sedation [3]. In trials, nausea, vomiting, diarrhea, abdominal pain and constipation each occurred in at least 5% of patients on the injection [3].
Whether insurance plans handle claims for the cardiovascular indication differently, and how much patients pay, is not addressed in the approval documents [1][3].
What happens next
The approval required Novo Nordisk to file its updated labeling in structured product labeling format within 14 days, and to bring any pending supplemental applications for the same drug into line with the new labeling [1]. Final promotional materials and prescribing information must reach the FDA when the company first puts them into use [1]. Any later change to the label would need its own review [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.